Synthesis and pharmacological evaluation of novel, selective CB2 ligands

CB2 ligands display lower incidence of CNS side effects compared to CB1 agonists. Accordingly, novel pharmacotherapies selectively targeting CB2 receptors may have considerable therapeutic potential. Significant medicinal chemistry efforts have been directed to the characterization of selective CB2 agonists, leading to the identification of compounds eliciting antinociceptive effects in models of acute pain, persistent inflammatory pain, post-operative pain, cancer pain, and neuropathic pain.


Researchers involved

  • Valentina Pedani - Ph.D. student